Disease · MONDO_0001879

anus cancer

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. anus cancer. Diseases, record MONDO_0001879. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001879

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: anus cancer; Open Targets
Open Targets ID: MONDO_0001879; Open Targets
Other names: cancer of anus, malignant anal neoplasm, malignant anal tumor, malignant anal tumour, malignant anus neoplasm, malignant neoplasm of anus, malignant neoplasm of the anus, malignant tumor of anus, malignant tumor of the anus, malignant tumour of anus, malignant tumour of the anus; Open Targets
Disease Ontology: DOID:14110; Disease Ontology
NCI Thesaurus: C7379; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 3 of its 7 drugs, from ClinicalTrials.gov; Open Targets

Drugs7

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
FLUOROURACIL	CHEMBL185	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
MITOMYCIN	CHEMBL105	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
CAPECITABINE	CHEMBL1773	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
CETUXIMAB	CHEMBL1201577	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
NANRILKEFUSP ALFA	CHEMBL5095385	Protein	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets3

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
TYMS	Thymidylate synthase	2	Thymidylate synthase inhibitor	Phase 3	https://conductscience.org/library/genes/7298	Drugs and targets
EGFR	Epidermal growth factor receptor	1	Epidermal growth factor receptor erbB1 inhibitor	Phase 2	https://conductscience.org/library/genes/1956	Drugs and targets
PDCD1	Programmed cell death protein 1	1	Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets

Trials11

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00316888	Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Anal Cancer	Phase 2	63	2016-08-29	Anal Cancer	CETUXIMAB, CISPLATIN, FLUOROURACIL	Open Targets' reading of its record	ClinicalTrials.gov
NCT00423293	Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal Cancer	Phase 2	63	2013-05-29	Anal Cancer	FLUOROURACIL, MITOMYCIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT02919969	Pembrolizumab in Metastatic Anal Cancer	Phase 2	38	2023-06-12	Anal Cancer	PEMBROLIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT01671488	A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer	Phase 1/2	11	2017-05-12	Anal Cancer	FLUOROURACIL, MITOMYCIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00003596	Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer	Phase 3	682		Anal Cancer	CISPLATIN, FLUOROURACIL, MITOMYCIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00025090	Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients With Primary Anal Cancer	Phase 3	600		Anal Cancer	CISPLATIN, FLUOROURACIL, MITOMYCIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT00003652	Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer	Phase 3	350		Anal Cancer	CISPLATIN, FLUOROURACIL	Open Targets' reading of its record	ClinicalTrials.gov
NCT04234113	Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors	Phase 1	115		Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer, Small-cell Lung Cancer, Bladder Cancer, Melanoma, Merkel Cell Carcinoma, Skin Squamous Cell Carcinoma, Microsatellite Instability High, Triple Negative Breast Cancer, Mesothelioma, Thymic Cancer, Cervical Cancer, Biliary Tract Cancer, Hepatocellular Carcinoma, Ovarian Cancer, Gastric Cancer, Head and Neck Squamous Cell Carcinoma, Anal Cancer	NANRILKEFUSP ALFA, PEMBROLIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT00068744	Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer	Phase 2/3	88		Anal Cancer	CISPLATIN, FLUOROURACIL, MITOMYCIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT05902533	REDEL Trial: Reduced Elective Nodal Dose for Anal Cancer Toxicity Mitigation	Phase 2/3	33		Anal Cancer	CAPECITABINE, MITOMYCIN	Open Targets' reading of its record	ClinicalTrials.gov

1 to 10 of 11

See all 11 trials

Comparisons in its trials1

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial
Arm I (Closed to Accrual as of 11/3/2008) vs Arm II (Open to Accrual on 8/18/2009): serious adverse events	26 of 28	29 of 34	62	NCT00316888

Source Trial comparisons

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
20564111	RESULT	1	PubMed
19643599	RESULT	1	PubMed
19139424	RESULT	1	PubMed
18430910	RESULT	1	PubMed
18191265	RESULT	1	PubMed
23150707	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001879

GET https://conductscience.org/api/diseases/v1/MONDO_0001879/drugs

API reference For AI assistants